Halozyme Therapeutics, Inc. (HALO)
Health Care ยท Biological Products, (No Diagnostic Substances)
Halozyme Therapeutics, Inc. (HALO) is listed on Nasdaq, where its shares have traded since March 12, 2004. SentiSense covers Halozyme Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Helen I. Torley is its chief executive officer. The company reports 423 employees, and its corporate website is www.halozyme.com.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Latest reported results
Halozyme Therapeutics, Inc. reported revenue of $481.0 million for Q2 FY2026, up 47.7% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 650 institutions reported holding HALO, with 122.9 million shares worth $9.6 billion in aggregate. The largest reported holders were BlackRock, Vanguard and State Street. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on HALO
- HALO sentiment: whether news and social coverage of Halozyme Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- HALO ownership: all 650 reporting institutions, plus insider and congressional trades.
- HALO financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Halozyme Therapeutics, Inc. do?
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies.
What sector is HALO in?
SentiSense classifies Halozyme Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does HALO stock trade?
Halozyme Therapeutics, Inc. (HALO) is listed on Nasdaq, where its shares have traded since March 12, 2004.
Who is the CEO of Halozyme Therapeutics, Inc.?
Helen I. Torley is the chief executive officer of Halozyme Therapeutics, Inc..